In a study with a cohort of 43 aplastic anemia patients by Winkler et al. (33), there were 5 patients with TET2 mutations at different points in Epag treatment, among which 3 were LOF truncating mutations and 2 missense alterations of unclear significance (Figure 5D). Here, TET2 is linked to aplastic anemia.